Anke-Hilse Matland-Van der Zee at the Breath Biopsy Conference 2022

00:00 Introduction

00:47 Talk

Question: In the supplement of the paper: Prediction of Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer by Electronic Nose Analysis of Exhaled Breath the sensitivity of the Spironose sensors are presented and these are all above 1ppm. I wonder what VOCs are actually detected with the Spironose when most VOCs are below 1ppm in breath (maybe except acetone or isoprene)? Are there abundant VOCs we currently overlook with GCMS.

Answer: Unfortunately, this is hard to answer using eNose technology. However, an eNose (contrary to GCMS) might use physical components (like oxygen, humidity, temperature, flow etc) next to the VOCs. You would expect that if the signal would only come purely from VOCs that research groups who focus on GCMS would have discovered (and validated) more VOCs by now. However, this is just speculation. No real answer to the question (yet!).

Talk Abstract:

In this talk I will discuss for which patients home measurements of exhaled breath might be useful. I will show some results of our work on detection of bacterial infections of CF patients with the help of volatile organic compounds in exhaled breath and on the effects of a viral infection on exhaled breath measurements in patients with asthma. Can we optimize treatment for the individual patient and optimize lung health by implementing breath measurements at home? Finally, I will discuss what the challenges of home breath measurements would be and how we might tackle those in the future.

Speaker Biography:
Anke-Hilse Maitland-Van der Zee was trained as a pharmacist, clinical pharmacologist and epidemiologist. In 2016 she was appointed full-professor in the AmsterdamUMC (Precision Medicine in Respiratory Disease). In 2005 she started to work at Utrecht University, first as assistant Professor and in 2012 as associate Professor in Precision Medicine. From 2003-2005 she worked as a post-doc at the Human Genetics Center of the University of Texas in Houston. Her main research goal is to bring precision medicine into clinical practice. Moving away from using old-fashioned diagnostic labels, but instead using biomarkers to understand biological pathways and optimize therapy for the individual patient accordingly. She is among others Principal Investigator of the strategic public private partnership Precision Medicine for More Oxygen (P4O2), president of the Federation Innovative Medicine Research Netherlands (FIGON) and president of theEuropean Association of Systems Medicine (EASYM). She published more than 300 peer reviewed articles.

The Breath Biopsy Conference 2023 is scheduled for 31^st October − 1st November. Click the button to express interest in the next Breath Biopsy Conference:

Express Interest